See more : Amada Co., Ltd. (6113.T) Income Statement Analysis – Financial Results
Complete financial analysis of Adial Pharmaceuticals, Inc. (ADIL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adial Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- LIXIL Corporation (JSGRY) Income Statement Analysis – Financial Results
- Cyber Power Systems, Inc. (3617.TW) Income Statement Analysis – Financial Results
- Founder SPAC (FOUN) Income Statement Analysis – Financial Results
- Jindal Stainless (Hisar) Limited (JSLHISAR.NS) Income Statement Analysis – Financial Results
- Indian Bank (INDIANB.NS) Income Statement Analysis – Financial Results
Adial Pharmaceuticals, Inc. (ADIL)
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 564.00 | 60.50K | 55.11K | 564.00 | 565.00 | 563.00 | 565.00 | 565.00 | 565.00 |
| Gross Profit | -564.00 | -60.50K | -55.11K | -564.00 | -565.00 | -563.00 | -565.00 | -565.00 | -565.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.27M | 4.18M | 8.40M | 5.85M | 3.97M | 368.46K | 182.11K | 146.14K | 322.11K |
| General & Administrative | 5.62M | 9.14M | 9.34M | 5.07M | 4.28M | 6.62M | 813.18K | 264.66K | 497.15K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.62M | 9.14M | 9.34M | 5.07M | 4.28M | 6.62M | 813.18K | 264.66K | 497.15K |
| Other Expenses | 0.00 | 0.00 | 46.49K | 2.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.89M | 13.32M | 17.74M | 10.93M | 8.24M | 6.99M | 995.29K | 410.81K | 819.26K |
| Cost & Expenses | 6.89M | 13.32M | 17.74M | 10.93M | 8.24M | 6.99M | 995.29K | 410.81K | 819.26K |
| Interest Income | 69.78K | 63.34K | 6.54K | 32.50K | 95.23K | 7.39K | 367.00 | 240.00 | 1.26K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 1.17M | 144.54K | 9.64K | 0.00 | |
| Depreciation & Amortization | 564.00 | 564.00 | 55.11K | 564.00 | 565.00 | 563.00 | 565.00 | 565.00 | 565.00 |
| EBITDA | -7.00M | -13.32M | -19.46M | -10.93M | -8.15M | -6.98M | -994.35K | -410.00K | -817.43K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -6.89M | -13.32M | -19.29M | -10.93M | -8.24M | -6.99M | -995.29K | -410.81K | -819.26K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -113.94K | 585.21K | -1.82M | 35.00K | -346.53K | -4.64M | -144.17K | -9.39K | 1.26K |
| Income Before Tax | -7.00M | -12.73M | -19.52M | -10.89M | -8.59M | -11.63M | -1.14M | -420.20K | -817.99K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -502.00 | -94.08K | -32.50K | -76.06K | -3.48M | 367.00 | 9.64K | 1.26K |
| Net Income | -7.00M | -12.73M | -19.42M | -10.86M | -8.59M | -11.63M | -1.14M | -420.20K | -817.99K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -5.44 | -11.98 | -26.12 | -21.79 | -21.80 | -61.10 | -5.20 | -2.20 | -4.28 |
| EPS Diluted | -5.44 | -11.98 | -26.12 | -21.79 | -21.80 | -61.10 | -5.20 | -2.20 | -4.28 |
| Weighted Avg Shares Out | 1.42M | 1.06M | 743.55K | 498.53K | 394.10K | 190.37K | 218.99K | 191.13K | 191.28K |
| Weighted Avg Shares Out (Dil) | 1.42M | 1.06M | 743.55K | 498.53K | 394.10K | 190.37K | 218.99K | 191.13K | 191.28K |
Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations
GLEN ALLEN, Va., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number...
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know
Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer
GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment...
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
Glen Allen, VA, October 23, 2024 – PRISM MediaWire – Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
GLEN ALLEN, Va., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it...
Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
GLEN ALLEN, Va., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced database lock for...
Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GLEN ALLEN, Va., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary...
Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
GLEN ALLEN, Va., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business...
Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04 Topline results expected during the fourth quarter GLEN ALLEN, Va., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the...
Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044
Expected New Patent Based on Extensive Review of Data and Information Expected New Patent Based on Extensive Review of Data and Information
Source: https://incomestatements.info
Category: Stock Reports